TMCnet News
HedgePath Pharmaceuticals Welcomes Three New Board Members [Global Data Point](Global Data Point Via Acquire Media NewsEdge) Mr. Cross, 41, is the President of the US subsidiary of Mayne Pharma (MYX.AX). Mr. Cross has more than 20 years of experience in the pharmaceutical industry. Prior to his current appointment, he served the Vice President, Business and Corporate Development of Mayne Pharma's primary operating company, where he was responsible for all in-licensing and out-licensing programs and research and development partnerships. Through HPPI's recently finalized Supply and License Agreement transactions with Mayne Pharma Venture Pty Ltd, Mayne Pharma has the right to appoint a member of HPPI's board of directors. Dr. Ono, 61, is a co-founder and since 2000 has served as a Venture Partner of the VIMAC Milestone Medica Fund LP, a Boston-based early-stage life sciences fund co-sponsored by VIMAC Ventures LLC and RBC Technology Ventures, Inc. Dr. Ono has 30 years of experience in managing public and private life science companies, including, from 1995 to 2000, serving as President and Chief Executive Officer of IntraImmune Therapies, Inc., which was sold to Abgenix, Inc. in 2000. Mr. Watson, 63, is a Certified Public Accountant with over 40 years experience in public accounting and auditing, having spent his entire career at Deloitte Touche Tohmatsu and its predecessor, most recently as Central Florida Marketplace Leader. He is expected to serve as Chairman of the Audit Committee of HPPI's board of directors. In connection with these appointments, Nicholas J. Virca, HPPI's President and Chief Executive Officer, who will report in his executive officer capacities to the newly constituted board, has voluntarily resigned his position as a board member. "We are most grateful to have these three highly qualified individuals join our board," stated Mr. Virca. "We believe these new board members, together with our Executive Chairman Frank O'Donnell and existing independent board member Sam Sears, provide HPPI with an excellent mix of professional expertise and corporate governance experience as we move our clinical development programs forward. I look forward to working with our new board." HPPI is presently working towards an anticipated 2014 filing of an Investigational New Drug (IND) Application aimed at securing FDA approval to begin a corporate-sponsored clinical trial with HPPI's primary drug candidate, SUBA™-Itraconazole for the treatment of basal cell carcinoma (BCC), and to commence and conduct such trial. HPPI holds the exclusive U.S. rights to SUBA-Itraconazole from Mayne Pharma for the treatment of cancer. Mayne Pharma will also supply SUBA-Itraconazole for HPPI's currently contemplated and future clinical trials. (c) 2014 GlobalData Provided by SyndiGate Media Inc. (Syndigate.info). |